Abstract
Background: Chromogranin-A (CgA) is a secretory protein processed into peptides that regulate angiogenesis and vascular cells activation, migration and proliferation. These processes may influence arterial inflammation and remodelling in Takayasu arteritis (TA). Methods: Plasma levels of full-length CgA (CgA439), CgA fragments lacking the C-terminal region (CgA-FRs) and the N-terminal fragment, CgA1-76 (vasostatin-1, VS-1) were analysed in 42 patients with TA and 20 healthy age-matched controls. Vascular remodelling was longitudinally assessed by imaging. CgA peptides were related to markers of systemic and local inflammation, disease activity and vascular remodelling. Results: Levels of CgA-FRs and VS-1 were increased in TA. Treatment with proton-pump inhibitors (PPIs) and arterial hypertension partially accounted for CgA levels and high inter-patient variability. CgA439, CgA-FRs and VS-1 levels did not reflect disease activity or extent. Markers of systemic or local inflammation correlated with higher CgA-FRs and VS-1 in normotensive patients and with higher CgA439 in hypertensive patients. Treatment with non-biologic anti-rheumatic agents was associated with increased CgA-FRs and a distinctive regulation of CgA processing. Reduced blood levels of anti-angiogenic CgA peptides were associated with vascular remodelling in the groups of patients on PPIs and with arterial hypertension. Conclusions: The plasma levels of CgA fragments are markedly increased in TA as a consequence of disease- and therapy-related variables. Anti-angiogenic forms of CgA may limit vascular remodelling. Given the effect of the various CgA peptides, it is advisable to limit the therapeutic prescriptions that might influence CgA-derived peptide levels to clearly agreed medical indications until further data become available.
| Original language | English |
|---|---|
| Article number | 187 |
| Journal | Arthritis Research and Therapy |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Aug 17 2016 |
Fingerprint
Keywords
- Biomarker
- Chromogranin A
- Proton-pump inhibitors
- Takayasu arteritis
- Vascular remodelling
- Vasculitis
ASJC Scopus subject areas
- Immunology and Allergy
- Rheumatology
- Immunology
Cite this
Chromogranin-A production and fragmentation in patients with Takayasu arteritis. / Tombetti, Enrico; Colombo, Barbara; Di Chio, Maria Chiara; Sartorelli, Silvia; Papa, Maurizio; Salerno, Annalaura; Bozzolo, Enrica Paola; Tombolini, Elisabetta; Benedetti, Giulia; Godi, Claudia; Lanzani, Chiara; Rovere-Querini, Patrizia; Del Maschio, Alessandro; Ambrosi, Alessandro; De Cobelli, Francesco; Sabbadini, Maria Grazia; Baldissera, Elena; Corti, Angelo; Manfredi, Angelo A.
In: Arthritis Research and Therapy, Vol. 18, No. 1, 187, 17.08.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chromogranin-A production and fragmentation in patients with Takayasu arteritis
AU - Tombetti, Enrico
AU - Colombo, Barbara
AU - Di Chio, Maria Chiara
AU - Sartorelli, Silvia
AU - Papa, Maurizio
AU - Salerno, Annalaura
AU - Bozzolo, Enrica Paola
AU - Tombolini, Elisabetta
AU - Benedetti, Giulia
AU - Godi, Claudia
AU - Lanzani, Chiara
AU - Rovere-Querini, Patrizia
AU - Del Maschio, Alessandro
AU - Ambrosi, Alessandro
AU - De Cobelli, Francesco
AU - Sabbadini, Maria Grazia
AU - Baldissera, Elena
AU - Corti, Angelo
AU - Manfredi, Angelo A.
PY - 2016/8/17
Y1 - 2016/8/17
N2 - Background: Chromogranin-A (CgA) is a secretory protein processed into peptides that regulate angiogenesis and vascular cells activation, migration and proliferation. These processes may influence arterial inflammation and remodelling in Takayasu arteritis (TA). Methods: Plasma levels of full-length CgA (CgA439), CgA fragments lacking the C-terminal region (CgA-FRs) and the N-terminal fragment, CgA1-76 (vasostatin-1, VS-1) were analysed in 42 patients with TA and 20 healthy age-matched controls. Vascular remodelling was longitudinally assessed by imaging. CgA peptides were related to markers of systemic and local inflammation, disease activity and vascular remodelling. Results: Levels of CgA-FRs and VS-1 were increased in TA. Treatment with proton-pump inhibitors (PPIs) and arterial hypertension partially accounted for CgA levels and high inter-patient variability. CgA439, CgA-FRs and VS-1 levels did not reflect disease activity or extent. Markers of systemic or local inflammation correlated with higher CgA-FRs and VS-1 in normotensive patients and with higher CgA439 in hypertensive patients. Treatment with non-biologic anti-rheumatic agents was associated with increased CgA-FRs and a distinctive regulation of CgA processing. Reduced blood levels of anti-angiogenic CgA peptides were associated with vascular remodelling in the groups of patients on PPIs and with arterial hypertension. Conclusions: The plasma levels of CgA fragments are markedly increased in TA as a consequence of disease- and therapy-related variables. Anti-angiogenic forms of CgA may limit vascular remodelling. Given the effect of the various CgA peptides, it is advisable to limit the therapeutic prescriptions that might influence CgA-derived peptide levels to clearly agreed medical indications until further data become available.
AB - Background: Chromogranin-A (CgA) is a secretory protein processed into peptides that regulate angiogenesis and vascular cells activation, migration and proliferation. These processes may influence arterial inflammation and remodelling in Takayasu arteritis (TA). Methods: Plasma levels of full-length CgA (CgA439), CgA fragments lacking the C-terminal region (CgA-FRs) and the N-terminal fragment, CgA1-76 (vasostatin-1, VS-1) were analysed in 42 patients with TA and 20 healthy age-matched controls. Vascular remodelling was longitudinally assessed by imaging. CgA peptides were related to markers of systemic and local inflammation, disease activity and vascular remodelling. Results: Levels of CgA-FRs and VS-1 were increased in TA. Treatment with proton-pump inhibitors (PPIs) and arterial hypertension partially accounted for CgA levels and high inter-patient variability. CgA439, CgA-FRs and VS-1 levels did not reflect disease activity or extent. Markers of systemic or local inflammation correlated with higher CgA-FRs and VS-1 in normotensive patients and with higher CgA439 in hypertensive patients. Treatment with non-biologic anti-rheumatic agents was associated with increased CgA-FRs and a distinctive regulation of CgA processing. Reduced blood levels of anti-angiogenic CgA peptides were associated with vascular remodelling in the groups of patients on PPIs and with arterial hypertension. Conclusions: The plasma levels of CgA fragments are markedly increased in TA as a consequence of disease- and therapy-related variables. Anti-angiogenic forms of CgA may limit vascular remodelling. Given the effect of the various CgA peptides, it is advisable to limit the therapeutic prescriptions that might influence CgA-derived peptide levels to clearly agreed medical indications until further data become available.
KW - Biomarker
KW - Chromogranin A
KW - Proton-pump inhibitors
KW - Takayasu arteritis
KW - Vascular remodelling
KW - Vasculitis
UR - http://www.scopus.com/inward/record.url?scp=84982126594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982126594&partnerID=8YFLogxK
U2 - 10.1186/s13075-016-1082-2
DO - 10.1186/s13075-016-1082-2
M3 - Article
VL - 18
JO - Arthritis Research and Therapy
JF - Arthritis Research and Therapy
SN - 1478-6354
IS - 1
M1 - 187
ER -